Welcome to our dedicated page for Piermont Valley Acquisition SEC filings (Ticker: CMCAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Piermont Valley Acquisition's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Piermont Valley Acquisition's regulatory disclosures and financial reporting.
Tigerless Health, Inc., a New York-based Insurtech platform, has agreed to a definitive business combination with Piermont Valley Acquisition Corp., a publicly traded SPAC, valuing Tigerless Health at an enterprise value of approximately $280 million.
After closing, the combined company is expected to be renamed Tigerless AI Holdings, Inc. and listed on NASDAQ, with all existing Tigerless Health shareholders rolling 100% of their equity. The deal is intended to support continued investment in the company’s proprietary AI capabilities that help consumers understand and navigate insurance.
The boards of both companies have unanimously approved the transaction, which is expected to close in the second half of 2026, subject to shareholder and regulatory approvals and other customary closing conditions. Founder and CEO Zikang Wu and his management team are expected to continue leading the combined company.
Piermont Valley Acquisition Corp. reported a Board change. On February 24, 2026, director Brian Coad resigned from the company’s Board of Directors.
The company stated that Mr. Coad’s resignation was not due to any disagreement regarding its operations, policies, or practices.
Piermont Valley Acquisition Corp (OTC: CMCAU/CMCAF/CMCAW) filed an 8-K on 11 July 2025 disclosing a change-of-control transaction, extensive board turnover and the cancellation of sponsor warrants.
Key terms of the Share Purchase Agreement signed by the Company, Vikasati Partners LLC (current sponsor) and Valleypark Road LLC (purchaser):
- The sponsor transferred 2,238,999 Class A ordinary shares and one Class B ordinary share to Valleypark Road LLC.
- The parties amended the original IPO letter agreement, and the sponsor granted the purchaser an irrevocable proxy over the shares the sponsor continues to hold.
- The sponsor and the former sponsor, CEMAC Sponsor LP, agreed to cancel 11,700,000 private-placement warrants that were purchased at the IPO.
- The Company will file and mail a Rule 14f-1 information statement. Ten days after mailing, the purchaser will be entitled to appoint additional directors, formalising the change in board control.
Management & board changes
- Effective 11 July 2025, Chief Executive Officer & Chairman Suresh Guduru, Chief Financial Officer Brian Coad and directors John Levy, Suresh Singamsetty and Kishore Kondragunta resigned. The Company reports no disagreements with the departing executives.
- Wei Qian was simultaneously appointed Chairman, Chief Executive Officer, Chief Financial Officer and Director. The Company will execute a standard indemnification agreement with Mr. Qian.
Regulatory filings & exhibits
- The 8-K includes the full Share Purchase Agreement as Exhibit 10.1 and an Inline XBRL cover-page file.
- No financial statements, pro forma data, or earnings information accompany the filing.
Investor take-aways
- Control shift: Transfer of founder equity and voting rights plus forthcoming board appointments constitute a formal change in control (Item 5.01).
- Dilution relief: Cancellation of 11.7 million private warrants removes a sizeable potential overhang that could have converted at $11.50.
- Leadership risk: Entire legacy leadership team has exited; the SPAC’s strategy now rests on a single newly appointed executive whose future plans are not yet disclosed.